Names | |
---|---|
IUPAC name
(15S,16R,18R)-16-Hydroxy-15-methyl-3-oxo-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaene-16-carboxylic acid
| |
Identifiers | |
CAS Number
|
|
3D model (JSmol)
|
|
ChEBI |
|
ChEMBL |
|
ChemSpider |
|
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
InChI
| |
SMILES
| |
Properties[1] | |
Chemical formula
|
C26H19N3O5 |
Molar mass | 453.454 g·mol−1 |
Appearance | White to light yellow powder |
Solubility | soluble in DMSO, methanol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
|
K252b is an ectoprotein kinase inhibitor, which is involved in the abolishment of the effects of nerve growth factors on PC12 and peripheral neuron system (PNS) neurons. When it is present in very low concentrations, it prolongs the survivorship of hippocampal, septal and cortical neurons deprived of glucose.[2]
K252b is related to K252a and staurosporine, which are low-molecular-weight alkaloids.[3] Staurosporine was discovered in 1977 while screening for microbial alkaloids using chemical detection methods. K252 was discovered in 1986 as a related natural indolocarbazole product. In 2007, K252b was found to have an inhibitory effect on mycobacterial protein kinase PknB. This is a receptor-like transmembrane protein. The PknB gene can be found in all known mycobacterial genomes. Staurosporine and K252a have inhibitory effects on the growth of Mycobacterium tuberculosis, but K252b failed to inhibit bacterial growth.